The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Formation of Antibodies to Factor VIII in Patients with Hemophilia A Who Are Treated with Interferon for Chronic Hepatitis C

Eveline P. Mauser-Bunschoten, MD, PhD; Marjolein Damen, MD; Henk W. Reesink, MD, PhD; Goris Roosendaal, MD; Robert A.F.M. Chamuleau, MD, PhD; and H. Marijke van den Berg, MD, PhD
[+] Article, Author, and Disclosure Information

From University Hospital Utrecht and Wilhelmina Children's Hospital, Utrecht, the Netherlands; and Red Cross Blood Bank, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, and Academic Medical Center, Amsterdam, the Netherlands. Requests for Reprints: Eveline P. Mauser-Bunschoten, MD, PhD, Van Creveld Clinic, University Hospital Utrecht, Postbox 85500, 3508 AG Utrecht, the Netherlands. Current Author Addresses: Drs. Mauser-Bunschoten, Roosendaal, and van den Berg: Van Creveld Clinic, University Hospital Utrecht, Postbox 85500, 3508 AG Utrecht, the Netherlands.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1996;125(4):297-299. doi:10.7326/0003-4819-125-4-199608150-00007
Text Size: A A A

Objective: To evaluate the risk for development of antibodies to factor VIII (factor VIII inhibitors) during and after interferon therapy in patients with hemophilia A and chronic hepatitis C infection.

Design: Patients were divided into two treatment groups and an untreated control group. Test results from the two treatment groups were compared with those from the control group.

Setting: 3 clinical centers in the Netherlands.

Patients: 35 men with hemophilia A who had acquired hepatitis C through the use of plasma-derived clotting factor concentrates.

Measurements: Patients were tested for factor VIII inhibitors before the start of interferon therapy and every 6 months thereafter.

Results: 21 patients with hemophilia A received interferon therapy for chronic hepatitis C infection for a mean of 19.5 months (range, 0.5 to 36 months). In 2 patients, inhibitors were detected on one occasion (maximum titer, 1.2 Bethesda units/mL) during interferon therapy. In 3 patients who were known to have had inhibitors before interferon therapy, no anamnestic reaction was seen during treatment. In 3 of 14 untreated controls who were followed for a mean of 28 months (range, 18 to 40 months), inhibitors were detected on one occasion (maximum titer, 2.3 Bethesda units/mL).

Conclusion: Long-term interferon therapy in patients with hemophilia did not increase the risk for development of factor VIII inhibitors.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.